CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents
SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.
CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline.
"Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, Pierre Fabre's Head of New Biologic Entity Platform and Director of Center of Immunology R&D Pierre Fabre. "We have chosen them as our partner for these reasons and look forward to what we are confident will be a successful alliance."
"We are very pleased that Pierre Fabre has selected us as a trusted partner to advance their cutting-edge immuno-oncology pipeline," said Jean-Pierre Wery, CrownBio's CEO. "Our unique capabilities will enable Pierre Fabre to continue providing new and improved therapies for the treatment of cancer."
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
marketing@crownbio.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Anaqua Transforms Foreign Patent Filing into a Strategic Advantage for Intellectual Property Professionals18.4.2024 13:00:00 CEST | Press release
BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Anaqua, the leading provider of innovation and intellectual property (IP) management technology for corporations, law firms and governments, announces advancements in its Foreign Filing offering, enhancing the capabilities of its IP management platform, AQX®. Anaqua has shifted the paradigm of foreign filing for IP professionals from a burdensome set of manual administrative tasks to a strategic and automated differentiator, powering rapid decision-making for global IP protection. In today’s competitive landscape, global IP practitioners understand the critical importance of protecting their innovation and inventions across borders. Anaqua’s advanced Foreign Filing within AQX offers a centralized ecosystem that addresses every aspect of the foreign filing lifecycle. On the AQX platform, customers can now utilize a decision workspace supported by competitive dashboards, foreign filing-specific reports, and online quoting to develop, execute, tr
Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention18.4.2024 13:00:00 CEST | Press release
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissipation of mechanical energy that could otherwise be transferred to the patient in a bonded dressing.1 The results show that layer-on-layer frictional sliding of ALLEVYN LIFE Dressing absorbs 30-45% of the mechanical energy, which could help alleviate pressure injury incidence in a patient's skin and underlying soft tissues. This novel mechanism of action further adds to our understanding of how multi-layer dressings such as ALLEVYN LIFE work when used prophylactically for PIP.1 “Based on my exten
Framgång för Terranet - tester utförda på AstaZeros testbana validerar BlincVisions potential18.4.2024 13:00:00 CEST | Pressemelding
Terranet AB (publ) har genomfört tester i AstaZeros testmiljö och erhållit för bolaget positiva utfall. Resultaten visar på stor potential för bolagets förarstödssystem BlincVision. Testerna har genomförts på en av Euro NCAP godkänd testanläggning, vilket innebär att dessa resultat direkt bidrar till Euro NCAP’s* ADAS betygsmetoder för 2026. Under hösten 2023 beviljades Terranet bidrag från innovationsmyndigheten Vinnova. Bidraget innebar att tillsammans med AstaZero utveckla nya provmetoder för avancerade förarstödssystem (ADAS), vilket nu har genomförts med framgång. Provmetoderna öppnar upp för betydande förbättringar inom trafiksäkerhet och för vad dagens och framtidens förarstödssystem kan åstadkomma. AstaZero är en välkänd testmiljö och godkänd av Euro NCAP, helt oberoende och skapad för att utvärdera framtidens trafiksäkerhet, särskilt för automatiserad körning och uppkopplade fordon. Det som gör AstaZero unikt är dess olika trafikmiljöer, som möjliggör testning av avancerade sä
Success for Terranet - tests conducted at AstaZero's test track validate BlincVision's potential18.4.2024 13:00:00 CEST | Press release
Terranet AB (publ) has conducted tests in AstaZero's test environment and obtained positive outcomes for the company. The results demonstrate significant potential for the company's Advanced Driver Assistance System, BlincVision. The tests have been conducted at a Euro NCAP-approved test facility, meaning that these results directly contribute to Euro NCAP's ADAS rating methods for 2026. In the fall of 2023, Terranet was granted funding from the innovation agency Vinnova. The funding entailed collaborating with AstaZero to develop new testing methods for Advanced Driver Assistance Systems (ADAS), which have now been successfully implemented. These testing methods pave the way for significant improvements in traffic safety and for what todays and future driver assistance systems can achieve. AstaZero is a well-known test environment approved by Euro NCAP, entirely independent and created to evaluate the safety of future traffic, particularly for automated driving and connected vehicles.
Decisions of Aspocomp Group Plc's Annual General Meeting 2024 and Board of Directors' organization meeting18.4.2024 12:50:00 CEST | Press release
Aspocomp Group Plc, Stock exchange release, April 18, 2024, at 1:50 p.m. (Finnish time) DECISIONS OF THE ANNUAL GENERAL MEETING 2024 The Annual General Meeting of Aspocomp Group Plc held on April 18, 2024, adopted the annual accounts and the consolidated annual accounts as well as granted the members of the Board of Directors and the CEO discharge from liability regarding the financial period 2023. The Annual General Meeting approved the Remuneration Report for the governing bodies 2023 and the Remuneration Policy for governing bodies 2024-2027. The Annual General Meeting decided that no dividend be paid for the fiscal year January 1- December 31, 2023. The Annual General Meeting decided to set the number of Board members at five (5) and reelected the current members of the Board Ms. Päivi Marttila, Ms. Kaarina Muurinen, Mr. Jukka Huuskonen and Mr. Anssi Korhonen and elected Mr. Ville Vuori as a new member of the Board for a term of office ending at the closing of the following Annual